MA48956A - Composés mic-1 et utilisations associées - Google Patents

Composés mic-1 et utilisations associées

Info

Publication number
MA48956A
MA48956A MA048956A MA48956A MA48956A MA 48956 A MA48956 A MA 48956A MA 048956 A MA048956 A MA 048956A MA 48956 A MA48956 A MA 48956A MA 48956 A MA48956 A MA 48956A
Authority
MA
Morocco
Prior art keywords
mic
compounds
associated uses
Prior art date
Application number
MA048956A
Other languages
English (en)
Inventor
Kilian Waldemar Conde Frieboes
Xiang Gao
Hongtao Guan
Kristian Tage Hansen
Lars Fogh Iversen
Sebastian Beck Jorgensen
Per Norgaard
Kristian Sass-Orum
Henning Thogersen
Yi Wang
Birgit Wieczorek
Xujia Zhang
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA48956A publication Critical patent/MA48956A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA048956A 2017-05-23 2018-05-23 Composés mic-1 et utilisations associées MA48956A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017085576 2017-05-23
CN2017113335 2017-11-28

Publications (1)

Publication Number Publication Date
MA48956A true MA48956A (fr) 2020-04-08

Family

ID=62567604

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048956A MA48956A (fr) 2017-05-23 2018-05-23 Composés mic-1 et utilisations associées

Country Status (17)

Country Link
US (3) US10398782B2 (fr)
EP (1) EP3630805A1 (fr)
JP (1) JP7015322B2 (fr)
KR (1) KR20200010353A (fr)
CN (1) CN111183148A (fr)
AU (1) AU2018272911B2 (fr)
BR (1) BR112019024102A2 (fr)
CA (1) CA3064320A1 (fr)
CL (1) CL2019003441A1 (fr)
CO (1) CO2019013768A2 (fr)
MA (1) MA48956A (fr)
MX (1) MX2019013801A (fr)
PE (1) PE20200514A1 (fr)
PH (1) PH12019550241A1 (fr)
RU (1) RU2019141031A (fr)
TW (1) TWI710377B (fr)
WO (1) WO2018215525A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
KR20210081389A (ko) 2018-10-22 2021-07-01 얀센 파마슈티카 엔.브이. 글루카곤 유사 펩티드 1(glp1)-성장 분화 인자 15(gdf15) 융합 단백질 및 이의 용도
WO2021067655A1 (fr) 2019-10-04 2021-04-08 Amgen Inc. Utilisation de gdf15 pour le traitement d'un syndrome cardiométabolique et d'autres affections
WO2021136223A1 (fr) * 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Protéines de fusion de glp-1 et de gdf15 et leurs conjugués
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートおよび使用の方法
WO2023154953A1 (fr) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes
EP4323413A4 (fr) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd Compositions pharmaceutiques liquides de conjugués polypeptidiques et leurs procédés d'utilisation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
PT2441466E (pt) 2004-04-13 2014-09-09 St Vincents Hosp Sydney Agente de inibição de mic-1
US20050256576A1 (en) 2004-05-13 2005-11-17 Moskowitz Nathan C Artificial expansile total lumbar and thoracic discs for posterior placement without supplemental instrumentation and its adaptation for anterior placement of artificial cervical, thoracic and lumbar discs
DK1751184T3 (da) 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
WO2006010891A2 (fr) 2004-07-26 2006-02-02 Asterion Limited Lieurs
CN101563358A (zh) 2006-10-13 2009-10-21 诺沃-诺迪斯克保健股份有限公司 融合于碱性蛋白标签的加工酶
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
ES2692495T3 (es) * 2009-01-23 2018-12-03 Novo Nordisk A/S Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
SI2393828T1 (sl) * 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
US9714276B2 (en) 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
TN2016000035A1 (en) 2013-07-31 2017-07-05 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CA2952293A1 (fr) 2014-06-24 2015-12-30 Novo Nordisk A/S Proteines de fusion mic-1 et leurs utilisations
HUE044783T2 (hu) * 2014-12-23 2019-11-28 Novo Nordisk As FGF21 származékok és alkalmazásaik
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
HRP20221530T1 (hr) 2015-10-02 2023-03-17 Julius-Maximilians-Universität Würzburg Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke
CA3000290C (fr) 2015-10-02 2023-02-21 Julius-Maximilians-Universitat Wurzburg Gdf-15 utilise comme marqueur diagnostique pour prevoir le resultat clinique d'un traitement avec des bloqueurs de point de controle immunitaire
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
WO2017109706A1 (fr) 2015-12-22 2017-06-29 Novartis Ag Méthodes de traitement ou d'amélioration de troubles métaboliques à l'aide du facteur-15 de croissance et de différenciation (gdf-15)
MA45113A (fr) * 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途

Also Published As

Publication number Publication date
CO2019013768A2 (es) 2020-04-01
MX2019013801A (es) 2020-01-30
EP3630805A1 (fr) 2020-04-08
WO2018215525A8 (fr) 2020-01-02
CL2019003441A1 (es) 2020-05-08
BR112019024102A2 (pt) 2020-06-02
WO2018215525A1 (fr) 2018-11-29
RU2019141031A (ru) 2021-06-16
PH12019550241A1 (en) 2020-12-07
JP2020520918A (ja) 2020-07-16
TWI710377B (zh) 2020-11-21
CN111183148A (zh) 2020-05-19
AU2018272911B2 (en) 2022-09-08
US10398782B2 (en) 2019-09-03
US20230364248A1 (en) 2023-11-16
KR20200010353A (ko) 2020-01-30
AU2018272911A1 (en) 2019-12-19
RU2019141031A3 (fr) 2021-07-16
US20180339057A1 (en) 2018-11-29
TW201900219A (zh) 2019-01-01
US20200079829A1 (en) 2020-03-12
CA3064320A1 (fr) 2018-11-29
PE20200514A1 (es) 2020-03-05
JP7015322B2 (ja) 2022-02-02

Similar Documents

Publication Publication Date Title
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
EP3694861A4 (fr) Composés hétérocycliques et leurs utilisations
EP3720430A4 (fr) Composés benzocarbonyle
EP3337486A4 (fr) Composés deutérés et leurs utilisations
EP3691623A4 (fr) Composés de benzosulfonyle
EP3595668A4 (fr) Composés de benzazépine, conjugués et utilisations associées
MA48956A (fr) Composés mic-1 et utilisations associées
MA52365A (fr) Composés et leurs utilisations
MA45857A (fr) Composés et compositions, et utilisations associées
EP3768269A4 (fr) Composés et leurs utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
EP3574701A4 (fr) Niveaux de priorité de configuration de ressources
MA43205A (fr) Composés pyy sélectifs et leurs utilisations
MA46589A (fr) Composés et utilisations de ces derniers
EP3700934A4 (fr) Composés et utilisations de ces composés
EP3426255A4 (fr) Composés antibactériens et utilisations de ceux-ci
EP3509589A4 (fr) Nouvelles utilisations
EP3838900A4 (fr) Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées
EP3450444A4 (fr) Composés de type crocine et utilisations correspondantes
EP3880194A4 (fr) Composés deutérés, compositions et utilisations
MA45113A (fr) Composés mic-1 et leur utilisation
EP3728289A4 (fr) Composés optimisés
MA41495A (fr) Composés benzoxaborole et leurs utilisations
EP3368011A4 (fr) Nouveaux composés et leurs utilisations
EP3716978A4 (fr) Composés de quinoxaline et leurs utilisations